The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 30, 2021

Filed:

Jun. 06, 2017
Applicants:

Yale University, New Haven, CT (US);

The Regents of the University of California, Oakland, CA (US);

The United States Government Represented BY the Department of Veterans Affairs, Washington, DC (US);

Inventors:

James E. Hansen, Guilford, CT (US);

Peter M. Glazer, Guilford, CT (US);

Richard H. Weisbart, Los Angeles, CA (US);

Robert N. Nishimura, Santa Monica, CA (US);

Grace Chan, Monterey Park, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); A61K 39/395 (2006.01); C07K 16/44 (2006.01); A61P 35/00 (2006.01); A61K 31/704 (2006.01); A61K 45/06 (2006.01); A61K 31/337 (2006.01); A61K 31/475 (2006.01); A61K 31/513 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2019.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/513 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/24 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 16/44 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01);
Abstract

Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies.


Find Patent Forward Citations

Loading…